Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 3 Study of the Safety and Efficacy of Nyxol (Phentolamine Ophthalmic Solution 0.75%) as a Single Agent and With Adjunctive Low-Dose Pilocarpine Hydrochloride Ophthalmic Solution 0.4% in Subjects With Presbyopia

NCT05646719 is registered in ClinicalTrials.gov with Ocuphire Pharma, Inc. as lead sponsor.

NCT NCT05646719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05646719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 3 Study of the Safety and Efficacy of Nyxol (Phentolamine Ophthalmic Solution 0.75%) as a Single Agent and With Adjunctive Low-Dose Pilocarpine Hydrochloride Ophthalmic Solution 0.4% in Subjects With Presbyopia
Lead sponsor
Ocuphire Pharma, Inc.
Phase
Phase 3
Overall status
Completed
Start date
December 22, 2022
Completion date
October 11, 2023
Enrollment
333 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

presbyopia